Reviva Pharmaceuticals Holdings, Inc.
RVPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $23 | $31 | $19 | $5 |
| G&A Expenses | $8 | $8 | $5 | $5 |
| SG&A Expenses | $8 | $8 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31 | $40 | $24 | $10 |
| Operating Income | -$31 | -$40 | -$24 | -$10 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | -$0 | $2 |
| Pre-Tax Income | -$30 | -$39 | -$24 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$39 | -$24 | -$9 |
| % Margin | – | – | – | – |
| EPS | -0.9 | -1.65 | -1.45 | -0.58 |
| % Growth | 45.5% | -13.8% | -150% | – |
| EPS Diluted | -0.9 | -1.65 | -1.45 | -0.58 |
| Weighted Avg Shares Out | 33 | 24 | 20 | 15 |
| Weighted Avg Shares Out Dil | 33 | 24 | 20 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $31 | $40 | $0 | $0 |
| EBITDA | -$30 | -$39 | -$24 | -$10 |
| % Margin | – | – | – | – |